A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
Status:
Completed
Trial end date:
2008-01-10
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate efficacy and tolerability, and number of positive
response to treatment with CAELYX (50 mg/m^2), administered as monotherapy once per 4 weeks
to patients with metastatic epithelial ovarian cancer, resistant to previous platinum
therapy.